Senseonics Holdings, Inc. SENS

SENS Company Overview

Senseonics Holdings, Inc. is a U.S.-based medical technology company focused on the development and commercialization of long-term continuous glucose monitoring (CGM) systems for people with diabetes. The company operates within the medical devices and digital health industries, with its primary business centered on implantable CGM technology designed to provide glucose monitoring over extended durations compared with traditional wearable sensors. Its flagship product family, the Eversense CGM system, combines an implantable fluorescent glucose sensor, a removable smart transmitter, and a mobile application platform.

The company’s primary revenue drivers include sales of CGM systems, related sensors and transmitters, and commercialization partnerships tied to diabetes management solutions. Senseonics primarily serves insulin-dependent diabetes patients, endocrinologists, diabetes clinics, and healthcare providers seeking longer-duration monitoring alternatives. A key differentiator is its implantable sensor technology, which allows extended sensor wear durations beyond many conventional transcutaneous CGM systems. Senseonics was founded in 1996 and evolved from an early-stage biosensor technology company into a specialized diabetes-device manufacturer, with increasing emphasis on strategic commercialization partnerships and regulatory expansion in North America and international markets.